A Phase III Study on the Safety, Pharmacokinetics and Efficacy of Coagulation Factor VIIa (Recombinant) in Congenital Hemophilia A or B Patients With Inhibitors to Factor VIII or IX
Latest Information Update: 18 Jan 2023
At a glance
- Drugs Recombinant factor VIIa (Primary)
- Indications Haemophilia A; Haemophilia B
- Focus Registrational; Therapeutic Use
- Acronyms PERSEPT 1
- Sponsors rEVO Biologics
- 13 Dec 2022 Results presented at the 64th American Society of Hematology Annual Meeting and Exposition
- 13 Dec 2022 Results assessing the efficacy of Recombinant-factor-VIIa presented at the 64th American Society of Hematology Annual Meeting and Exposition.
- 15 Jul 2022 According to LFB media release, the European Medicines Agency (EMA) has granted a Marketing Authorisation for CEVENFACTA (eptacog beta) for the treatment of bleeding episodes and for the prevention of bleeding in those undergoing surgery or invasive procedures, based on data from PERSEPT 1 and PERSEPT 3 studies.